DoDeEv
DoDeEv
10 августа 2022 в 20:38
$DCPH опасно! Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Journal of Clinical Oncology has published results from its INTRIGUE Phase 3 study of QINLOCK® (ripretinib) in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib. Although QINLOCK did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, QINLOCK showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events (TEAEs) and improved tolerability.
17 $
30,94%
Нравится
Не является индивидуальной инвестиционной рекомендацией
22 комментария
Ваш комментарий...
g
gde_ya_1807
10 августа 2022 в 20:44
Бежать?
Нравится
DoDeEv
10 августа 2022 в 20:47
@gde_ya_1807 INTRIGUE is an international, multi-center study conducted in 122 active sites across 22 countries, where 453 patients with second-line GIST were randomized to receive ripretinib (n=226) or sunitinib (n=227). Key study results include: • In patients with a KIT exon 11 primary mutation, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm (Hazard Ratio [HR] 0.88, p=0.36). In the intention-to-treat (ITT) population (n=453), ripretinib demonstrated an mPFS of 8.0 months compared to 8.3 months for the sunitinib arm (HR 1.05, nominal p value=0.72). • In patients with a KIT exon 11 primary mutation, ripretinib demonstrated an objective response rate (ORR) of 23.9% (n=39 of 163) compared to 14.6% (n=24 of 164) for sunitinib (nominal p value=0.03). In the ITT population, ripretinib demonstrated an ORR of 21.7% (n=49 of 226) compared to 17.6% (n=40 of 227) for sunitinib (nominal p value=0.27). • Ripretinib was generally well tolerated. Fewer patients in the ripretinib arm experienced Grade 3/4 treatment-emergent adverse events compared to sunitinib (41.3% vs 65.6%).
Нравится
DoDeEv
10 августа 2022 в 20:48
Patients receiving sunitinib were three times more likely to develop Grade 3 hypertension compared to patients receiving ripretinib (26.7% vs. 8.5%) and patients receiving sunitinib were seven times more likely to develop Grade 3 palmar-plantar erythrodysesthesia compared to patients receiving ripretinib (10.0% vs. 1.3%). • Patient reported outcome measures also showed a more favorable tolerability profile for patients receiving ripretinib compared to patients receiving sunitinib. Patients receiving ripretinib experienced less deterioration in their ability to engage in either work or leisure activities during treatment, and fewer patients receiving ripretinib experienced moderate to extremely large impact on their lives due to skin toxicity across treatment cycles compared to patients receiving sunitinib.
Нравится
DoDeEv
10 августа 2022 в 20:49
@gde_ya_1807 дадут ниже зайти, вернусь. Пока посижу посмотрю, двояко.
Нравится
DoDeEv
10 августа 2022 в 20:51
Не нравится фраза: did not offer a statistically significant improvement in progression-free survival compared to sunitinib.
Нравится
Анализ компаний
Подробные обзоры финансового потенциала компаний
Invest_or_lost
+23,2%
21,2K подписчиков
FinDay
+46,9%
26,1K подписчиков
Mistika911
+14,7%
21,2K подписчиков
Совкомбанк: сильные итоги 2023 года, но потенциал роста акций ограничен
Обзор
|
Сегодня в 15:56
Совкомбанк: сильные итоги 2023 года, но потенциал роста акций ограничен
Читать полностью
DoDeEv
19 подписчиков13 подписок
Портфель
до 1 000 000 
Доходность
+48,3%
Еще статьи от автора
23 февраля 2024
Очередной пакет в пакет с пакетами. Продолжаем покупать. SNGSP TRMK UGLD TRNFP UPRO
15 ноября 2023
ISSUANCEUZHZ в планку при открытии торгов?
30 августа 2023
UPRO распределим денежки на дивиденды?)